Why Aardvark Therapeutics, Inc.’s (AARD) Stock Is Down 5.79%
As of Friday, September 18, Aardvark Therapeutics, Inc.’s AARD share price has dipped by 5.79%, which has investors questioning if this is right time to buy.Michael Rose
Stock Evaluator: Aardvark Therapeutics, Inc. (AARD)
Aardvark Therapeutics, Inc. AARD
$5.38
-0.15
-2.71%
September 18, 2026 4:00:00 PM
EST
Volume: 129,808
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Pharmaceuticals |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Aardvark Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.
Commentary & Analysis
Why Aardvark Therapeutics, Inc.’s (AARD) Stock Is Up 8.93%
As of Thursday, September 17, Aardvark Therapeutics, Inc.’s AARD share price has surged by 8.93%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Aardvark Therapeutics, Inc.’s (AARD) Stock Is Down 5.23%
As of Tuesday, September 15, Aardvark Therapeutics, Inc.’s AARD share price has dipped by 5.23%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Aardvark Therapeutics, Inc.’s (AARD) Stock Is Up 7.89%
As of Monday, September 14, Aardvark Therapeutics, Inc.’s AARD share price has surged by 7.89%, which has investors questioning if this is right time to sell.Michael Rose
Why Aardvark Therapeutics, Inc.’s (AARD) Stock Is Up 13.06%
As of Monday, September 14, Aardvark Therapeutics, Inc.’s AARD share price has surged by 13.06%, which has investors questioning if this is right time to sell.Omar Beirat
Financial Summary
| Share Statistics | AARD | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $117.7 | $586.4 | 23% |
|
| Shares Out (Mil) | 21.8 | 43.1 | 32% |
|
| Institutional Ownership | 54.9% | 83.7% | 37% |
|
| Float (Mil) | 11.0 | 45.1 | 20% |
|
| Beta | na | 0.73 | na |
|
| Avg Daily Volume (000s) | 173 | 331 | 41% |
|
| Price Change (52-week) |
(51.0%) | 63.2% | 16% |
|
| Growth | AARD | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.7% | na |
|
| Net Income (5yr) | na | (1.4%) | na |
|
| EPS (5yr) | na | 15.1% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.0%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 9 | 8 | 9 | |
| Current EPS | ($0.772) | ($3.168) | ($2.782) | |
| Month Ago EPS | ($0.772) | ($3.168) | ($2.782) | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 1 | 1 | 1 | |
| Three Months Ago EPS | ($0.869) | ($3.651) | ($3.238) | |
| Year/Year Chg | 17.1% | 7.9% | (17.6%) | |
| Financials | AARD | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $317 | na |
|
| Net Income (TTM) (Mil) | ($70) | ($11) | 14% |
|
| EPS (TTM) | ($3.205) | ($0.600) | 11% |
|
| Operating Cash Flow (TTM) (Mil) | ($69) | ($6) | 8% |
|
| Net Cash Flow (TTM) (Mil) | $48 | $5 | 69% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $6 | 13% |
|
| Enterprise Value (Q1) (Mil) | $56 | $515 | 17% |
|
| Valuation | AARD | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.57 | 2.51 | 42% |
|
| P/E | na | 17.1 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | AARD | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 69.4% | na |
|
| Net Margin | na | 2.5% | na |
|
| ROA | (61.1%) | (22.4%) | 10% |
|
| ROE | (66.0%) | (21.8%) | 13% |
|
| Liabilities to Assets | 8.2% | 32.4% | 5% |
|
| F-Score | 2 | 3 | 7% |
|
Aardvark Therapeutics, Inc. did not pass any screens on 9/18/2026.
